Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Combinations of anthracycline, taxane and fluoropyrimidine are highly active in advanced breast cancer (ABC). In a phase II study of epirubicin 50 mg/m(2), docetaxel 75 mg/m(2), and infusional 5-FU 200 mg/m(2)/day, we found dose-limiting neutropenia and frequent central venous catheter complications. An alternative approach has been tested using weekly fractionation of docetaxel, and oral capecitabine. METHODS: Initially, six women with ABC were treated with epirubicin 60 mg/m(2) day 1, docetaxel 25 mg/m(2) days 1,8,15, and capecitabine 1,000 mg/m(2) twice daily days 1-14, every 21 days. Six further patients received the above with capecitabine escalated to 1,500 mg/m(2) RESULTS: Four DLTs occurred in six patients at the second dose level (febrile neutropenia in 2). There were frequent dose delays/reductions, and fatigue, nausea/vomiting, and diarrhoea were common. Overall, six of ten assessable patients achieved a partial response. CONCLUSIONS: An active regimen, but significant haematological toxicity precluded dose further escalation.

Original publication

DOI

10.1007/s00280-009-1021-x

Type

Journal article

Journal

Cancer Chemother Pharmacol

Publication Date

07/2009

Volume

64

Pages

407 - 412

Keywords

Administration, Oral, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Breast Neoplasms, Capecitabine, Deoxycytidine, Dose-Response Relationship, Drug, Epirubicin, Female, Fluorouracil, Humans, Infusions, Intravenous, Liver Neoplasms, Lung Neoplasms, Middle Aged, Neoplasm Staging, Prognosis, Soft Tissue Neoplasms, Survival Rate, Taxoids, Treatment Outcome, Young Adult